A Streamline Strategy for Indication and Length of Telemetry Monitoring After TAVR
Catheterization and Cardiovascular Interventions · 2026
DOI: 10.1002/ccd.70299 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2026. Verfasst von Antonin Fournier und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, CHU Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Telemetry, Arrhythmias, Cardiac, Aortic Valve Stenosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Both indication and length of ECG telemetry monitoring (TM) after transcatheter aortic valve replacement (TAVR) are not well defined.
Aims
We hypothesize that a targeted strategy for monitoring conductive disorders (CD) post‐TAVR can reduce the need and duration of in‐hospital TM without compromising safety.
Methods
We prospectively evaluated consecutive patients undergoing transfemoral TAVR between February 2023 and September 2024. Intensive care unit (ICU) transfer for TM was considered when previous right bundle branch block or when new or worsening CD. TM duration was standardized, from 24 to 48 h. The primary endpoint was incidence of severe CD, defined as symptomatic or requiring medical intervention, occurring outside the ICU, at 1‐month follow‐up.
Results
Among 250 patients included (mean age: 80.53 ± 6.86 years), 138 (55.20%) required TM, mainly due to new left bundle branch block ( n = 64, 44.80%). By respecting the protocol, the primary endpoint was achieved for three patients (1.20%, 95% CI: 0.31; 3.77), all related to post‐discharge CD occurring after Day 6 and requiring permanent pacemaker implantation (PPI). There were no deaths and no severe in‐hospital CD outside the ICU. The PPI rate was 16.80%. The mean ICU length of stay was 1.34 days. Absence of TM was associated with shorter mean global hospitalization duration (1.43 vs. 2.93 days, p < 0.001).
Conclusion
Selective indication and length of TM after TAVR is possible with no in‐hospital events, no deaths, and a low rate of rhythmic events after hospital discharge, confirming the safety of this in‐hospital strategy. Nearly half of the patients did not require TM, and very short global and ICU lengths were observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, CHU Montpellier, Montpellier, France.
- Department of Cardiology, CHU Nîmes, Nîmes, France.
- Clinical Research and Epidemiology Unit, CHU Montpellier, Univ Montpellier, Montpellier, France.
- Department of Cardiac Surgery, CHU Montpellier, Montpellier, France.
ORCID-Profile: Antonin Fournier, Benoit Lattuca, Jean-Christophe Macia, François Roubille, Florence Leclercq
Zitieren
APA
Fournier, A., Robert, P., Lattuca, B., Duflos, C., Duroyon, M. M., Macia, J. C., Schmutz, L., Steinecker, M., Berdeu, J. M., Gandet, T., Pasquie, J. L., Roubille, F., Cayla, G., & Leclercq, F. (2026). A Streamline Strategy for Indication and Length of Telemetry Monitoring After TAVR. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70299
Vancouver
Fournier A, Robert P, Lattuca B, Duflos C, Duroyon MM, Macia JC, et al. A Streamline Strategy for Indication and Length of Telemetry Monitoring After TAVR. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70299
BibTeX
@article{Fournier2026,
author = {Fournier, Antonin and Robert, Pierre and Lattuca, Benoit and Duflos, Claire and Duroyon, Maël-Morvan and Macia, Jean-Christophe and Schmutz, Laurent and Steinecker, Matthieu and Berdeu, Jean-Michel and Gandet, Thomas and Pasquie, Jean Luc and Roubille, François and Cayla, Guillaume and Leclercq, Florence},
title = {A Streamline Strategy for Indication and Length of Telemetry Monitoring After TAVR},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
doi = {10.1002/ccd.70299}
}
EUVIMED